Guggenheim Capital’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Guggenheim Capital’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-49,849	Closed	-$447K	–	3104
2016 Q3	$447K	Buy	+49,849	New	+$354K	﹤0.01%	2427
2015 Q3	–	Sell	-401,391	Closed	-$6.34M	–	3142
2015 Q2	$6.34M	Buy	+401,391	New	+$4.88M	0.02%	1047
2014 Q4	–	Sell	-212,779	Closed	-$2.04M	–	3249
2014 Q3	$2.04M	Buy	212,779 +98,321	+86%	+$1M	﹤0.01%	1757
2014 Q2	$1.32M	Sell	114,458 -137,647	-55%	-$1.25M	﹤0.01%	2108
2014 Q1	$2.52M	Buy	252,105 +49,120	+24%	+$709K	0.01%	1593
2013 Q4	$2.64M	Buy	+202,985	New	+$2.8M	0.01%	1526

Guggenheim Capital's RPTP Position: Q4 2016 in Review

Guggenheim Capital sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 49,849 shares — an estimated $447K sold.

Guggenheim Capital first reported a position in RPTP in Q4 2013 and held it in 6 quarters. The position peaked at $6.34M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

Guggenheim Capital reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
Guggenheim Capital sold 49,849 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $447K.
Guggenheim Capital first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q4 2013 and held it in 6 quarters.
Guggenheim Capital's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $6.34M in Q2 2015.
0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on Guggenheim Capital's 13F filing for Q4 2016, filed 14 Feb 2017.